Mannkind Corp (MNKD) 5.47 $MNKD
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST
VEEV: 24.63 (-0.10), NG: 3.26 (-0.19), CRIS: 3.04 (-0.29), EVTC: 21.77 (+0.27), GTN: 12.60 (+0.29), SM: 44.49 (-1.81), MNKD: 5.47 (-0.26), RIGL: 3.56 (+0.26), EXK: 1.96 (-0.09), WBAI: 14.50 (+0.70)
Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), ARWR: 7.75 (-0.19), SPHS: 0.70 (-0.03), BSX: 16.56 (-0.41), MDVN: 126.55 (-0.53), JNJ: 100.11 (-2.41), AAC: 29.30 (-2.80), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), SMMT: 10.29 (+0.10), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), MNK: 121.33 (-0.37), AQXP: 10.49 (+0.43), PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), CELG: 118.03 (-2.68), OREX: 7.10 (-0.91), PODD: 32.24 (+0.26), GERN: 3.50 (-0.28), TEVA: 56.40 (-0.11), TCON: 17.57 (+0.36), NVS: 97.46 (-1.49)
Technical Analysis of Wal-Mart, Coca-Cola, MannKind and Las Vegas Sands
Kumar Abhishek - Amigobulls - Thu Mar 05, 7:02AM CST
Coca-Cola stock price has again found support at 100 day SMA. The 100 day SMA has provided support to coca cola stock price on multiple occasions.
KO: 41.52 (-0.88), WMT: 82.59 (-0.98), LVS: 55.09 (-1.27), MNKD: 5.47 (-0.26)
5 Things MannKind Corporation's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 05, 6:21AM CST
MannKind 's fourth-quarter conference was only 31 minutes long, but the call contained some tidbits of insight from the biotech's management that investors should know. Source: MannKind. "In fact, we were just, the other day, asked if we...
SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
MannKind: Use This Drop As An Opportunity
Kumquat Research - at Seeking Alpha - Wed Mar 04, 7:33AM CST
MNKD: 5.47 (-0.26)
MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade
at The Street - Tue Mar 03, 3:22PM CST
Here's a technical look at the stock after a brutal downgrade.
MNKD: 5.47 (-0.26)
New Buy Ins And Profit Taking: The Well-Valued Growth Portfolio This Month
Psycho Analyst - at Seeking Alpha - Tue Mar 03, 1:05PM CST
ODFL: 77.51 (-0.13), ESRX: 82.27 (-2.01), THO: 61.35 (-0.02), SWKS: 90.75 (-0.80), LGIH: 13.66 (-0.23), LKQ: 23.83 (-0.32), DG: 71.32 (-0.39), MNKD: 5.47 (-0.26), LUV: 43.30 (-0.80)
Why MannKind Corp. Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Tue Mar 03, 10:48AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of MannKind Corp. fell by more than 14% on...
GS: 186.91 (-3.17), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
Potential Afrezza discounts and challenging competitive landscape behind Goldman downgrade of MannKind
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 10:46AM CST
LLY: 68.41 (-2.18), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'
at The Street - Tue Mar 03, 10:28AM CST
Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.
MNKD: 5.47 (-0.26)
Forget Biased Analysts, Diabetics Love MannKind's Afrezza
Maredin Capital Advisors - Seeking Alpha - Tue Mar 03, 9:32AM CST
The MannKind (ticker " MNKD "
story/plot continues to thicken Over the past several years, investors, both long and short, have had to rely on trial data, and the opinions of analysts to guide their investment decisions. This led to a...
MNKD: 5.47 (-0.26)
MannKind off 10% premarket on Goldman downgrade
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:24AM CST
MNKD: 5.47 (-0.26)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 3.32 (-0.05), ONCY: 0.90 (-0.15), PLUG: 2.97 (+0.01), OCN: 8.91 (+0.24), XON: 50.16 (+0.66), TEDU: 10.24 (+0.21), BIOC: 3.10 (-0.26), LL: 33.32 (-0.51), MNKD: 5.47 (-0.26), CYCC: 1.05 (-0.01), CYTX: 1.11 (-0.05), DATE: 5.06 (-0.04), TSEM: 17.50 (-0.31), LEAF: 48.59 (-1.19), FNJN: 2.42 (-0.10), AMCO: 1.28 (-0.02)
MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch
at The Street - Tue Mar 03, 7:16AM CST
The slow commercial launch of the inhaled insulin Afrezza coupled with growing downward pricing pressure for all diabetes products compels Goldman Sachs to slap a 'sell' rating on MannKind.
SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
Downgrade Alert for MannKind (MNKD)
Comtex SmarTrend(R) - Tue Mar 03, 7:00AM CST
MannKind (NASDAQ:MNKD) was downgraded from Neutral to Sell at Goldman Sachs today. The stock closed yesterday at $6.64 on volume of 6.1 million shares, below average daily volume of 6.3 million. MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Companys lead investigational product candidate is the Technosphere Insulin System.
MNKD: 5.47 (-0.26)
Institutions Lend Out MannKind Shares To Make Profits But Depress The Price As Well
Austin Moss - at Seeking Alpha - Mon Mar 02, 9:57AM CST
MNKD: 5.47 (-0.26)
MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
at The Street - Mon Mar 02, 7:15AM CST
Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.
NVO: 46.51 (-0.33), LLY: 68.41 (-2.18), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
Analysts Weigh In On MannKind Following Q4 Results
TipRanks - at Seeking Alpha - Sat Feb 28, 7:32AM CST
By Carly Forster MannKind Corporation (NASDAQ: MNKD ) announced its fourth-quarter fiscal 2014 earnings report on Wednesday, February 24th, with results generally in line with expectations. Highlights from the report include a loss of -$0.09 a...
MNKD: 5.47 (-0.26)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.80 (-0.11), VRX: 198.71 (-5.24), ACT: 289.92 (-5.78), PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CLDX: 29.39 (-0.39), HSP: 87.90 (+0.05), AGN: 233.51 (-1.90), JNJ: 100.11 (-2.41), ATOS: 1.97 (-0.04), ONVO: 5.59 (-0.13), PTCT: 71.13 (-1.59), SNY: 47.42 (-0.94), PTLA: 41.72 (-0.13), INCY: 90.00 (-1.97), PFE: 33.97 (-0.50), CPHR: 11.67 (-0.33), MYL: 55.44 (-1.25), AMGN: 154.88 (-4.72), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), NKTR: 13.02 (-0.28), OMER: 26.14 (-0.21), DVA: 77.63 (+0.70), GILD: 101.81 (-1.61), SGEN: 35.32 (-0.28), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), TEVA: 56.40 (-0.11), BIL: 45.72 (-0.01), ARIA: 8.08 (-0.17), NVS: 97.46 (-1.49)
Why Second Sight Medical Products Inc. Vaulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 27, 12:41PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Al Mann's vision-restoring...
EYES: 17.44 (+0.37), MNKD: 5.47 (-0.26)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST
VEEV: 24.63 (-0.10), NG: 3.26 (-0.19), CRIS: 3.04 (-0.29), EVTC: 21.77 (+0.27), GTN: 12.60 (+0.29), SM: 44.49 (-1.81), MNKD: 5.47 (-0.26), RIGL: 3.56 (+0.26), EXK: 1.96 (-0.09), WBAI: 14.50 (+0.70)
Seeking Alpha's Biotech Weekly: AbbVie - Pharmacyclitics, Orexigen Confusion, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), ARWR: 7.75 (-0.19), SPHS: 0.70 (-0.03), BSX: 16.56 (-0.41), MDVN: 126.55 (-0.53), JNJ: 100.11 (-2.41), AAC: 29.30 (-2.80), ABBV: 55.64 (-1.22), SNY: 47.42 (-0.94), SMMT: 10.29 (+0.10), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), MNK: 121.33 (-0.37), AQXP: 10.49 (+0.43), PFE: 33.97 (-0.50), AMGN: 154.88 (-4.72), GSK: 46.73 (-0.87), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), CELG: 118.03 (-2.68), OREX: 7.10 (-0.91), PODD: 32.24 (+0.26), GERN: 3.50 (-0.28), TEVA: 56.40 (-0.11), TCON: 17.57 (+0.36), NVS: 97.46 (-1.49)
Technical Analysis of Wal-Mart, Coca-Cola, MannKind and Las Vegas Sands
Kumar Abhishek - Amigobulls - Thu Mar 05, 7:02AM CST
Coca-Cola stock price has again found support at 100 day SMA. The 100 day SMA has provided support to coca cola stock price on multiple occasions.
KO: 41.52 (-0.88), WMT: 82.59 (-0.98), LVS: 55.09 (-1.27), MNKD: 5.47 (-0.26)
5 Things MannKind Corporation's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 05, 6:21AM CST
MannKind 's fourth-quarter conference was only 31 minutes long, but the call contained some tidbits of insight from the biotech's management that investors should know. Source: MannKind. "In fact, we were just, the other day, asked if we...
SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
MannKind: Use This Drop As An Opportunity
Kumquat Research - at Seeking Alpha - Wed Mar 04, 7:33AM CST
MNKD: 5.47 (-0.26)
MannKind's Charts Suggest Waiting on the Stock After Goldman's Downgrade
at The Street - Tue Mar 03, 3:22PM CST
Here's a technical look at the stock after a brutal downgrade.
MNKD: 5.47 (-0.26)
New Buy Ins And Profit Taking: The Well-Valued Growth Portfolio This Month
Psycho Analyst - at Seeking Alpha - Tue Mar 03, 1:05PM CST
ODFL: 77.51 (-0.13), ESRX: 82.27 (-2.01), THO: 61.35 (-0.02), SWKS: 90.75 (-0.80), LGIH: 13.66 (-0.23), LKQ: 23.83 (-0.32), DG: 71.32 (-0.39), MNKD: 5.47 (-0.26), LUV: 43.30 (-0.80)
Why MannKind Corp. Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Tue Mar 03, 10:48AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of MannKind Corp. fell by more than 14% on...
GS: 186.91 (-3.17), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
Potential Afrezza discounts and challenging competitive landscape behind Goldman downgrade of MannKind
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 10:46AM CST
LLY: 68.41 (-2.18), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
Cramer: Goldman's Negative MannKind Report Creates 'Problematic Situation'
at The Street - Tue Mar 03, 10:28AM CST
Cramer says the negative Goldman Sachs is having an unhealthy effect on MannKind's stock.
MNKD: 5.47 (-0.26)
Forget Biased Analysts, Diabetics Love MannKind's Afrezza
Maredin Capital Advisors - Seeking Alpha - Tue Mar 03, 9:32AM CST
The MannKind (ticker " MNKD "
story/plot continues to thicken Over the past several years, investors, both long and short, have had to rely on trial data, and the opinions of analysts to guide their investment decisions. This led to a... MNKD: 5.47 (-0.26)
MannKind off 10% premarket on Goldman downgrade
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:24AM CST
MNKD: 5.47 (-0.26)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST
MDR: 3.32 (-0.05), ONCY: 0.90 (-0.15), PLUG: 2.97 (+0.01), OCN: 8.91 (+0.24), XON: 50.16 (+0.66), TEDU: 10.24 (+0.21), BIOC: 3.10 (-0.26), LL: 33.32 (-0.51), MNKD: 5.47 (-0.26), CYCC: 1.05 (-0.01), CYTX: 1.11 (-0.05), DATE: 5.06 (-0.04), TSEM: 17.50 (-0.31), LEAF: 48.59 (-1.19), FNJN: 2.42 (-0.10), AMCO: 1.28 (-0.02)
MannKind Rating, Price Target Are Cut by Goldman on Slow Afrezza Launch
at The Street - Tue Mar 03, 7:16AM CST
The slow commercial launch of the inhaled insulin Afrezza coupled with growing downward pricing pressure for all diabetes products compels Goldman Sachs to slap a 'sell' rating on MannKind.
SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
Downgrade Alert for MannKind (MNKD)
Comtex SmarTrend(R) - Tue Mar 03, 7:00AM CST
MannKind (NASDAQ:MNKD) was downgraded from Neutral to Sell at Goldman Sachs today. The stock closed yesterday at $6.64 on volume of 6.1 million shares, below average daily volume of 6.3 million. MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Companys lead investigational product candidate is the Technosphere Insulin System.
MNKD: 5.47 (-0.26)
Institutions Lend Out MannKind Shares To Make Profits But Depress The Price As Well
Austin Moss - at Seeking Alpha - Mon Mar 02, 9:57AM CST
MNKD: 5.47 (-0.26)
MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
at The Street - Mon Mar 02, 7:15AM CST
Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.
NVO: 46.51 (-0.33), LLY: 68.41 (-2.18), SNY: 47.42 (-0.94), MNKD: 5.47 (-0.26)
Analysts Weigh In On MannKind Following Q4 Results
TipRanks - at Seeking Alpha - Sat Feb 28, 7:32AM CST
By Carly Forster MannKind Corporation (NASDAQ: MNKD ) announced its fourth-quarter fiscal 2014 earnings report on Wednesday, February 24th, with results generally in line with expectations. Highlights from the report include a loss of -$0.09 a...
MNKD: 5.47 (-0.26)
Seeking Alpha's Biotech Weekly: Achillion Overdone, Sanofi's Toujeo A Go, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.80 (-0.11), VRX: 198.71 (-5.24), ACT: 289.92 (-5.78), PCYC: 254.56 (+0.34), MDT: 76.48 (-2.02), CAH: 87.01 (-1.94), CLDX: 29.39 (-0.39), HSP: 87.90 (+0.05), AGN: 233.51 (-1.90), JNJ: 100.11 (-2.41), ATOS: 1.97 (-0.04), ONVO: 5.59 (-0.13), PTCT: 71.13 (-1.59), SNY: 47.42 (-0.94), PTLA: 41.72 (-0.13), INCY: 90.00 (-1.97), PFE: 33.97 (-0.50), CPHR: 11.67 (-0.33), MYL: 55.44 (-1.25), AMGN: 154.88 (-4.72), LLY: 68.41 (-2.18), BMY: 65.12 (-0.93), MNKD: 5.47 (-0.26), NKTR: 13.02 (-0.28), OMER: 26.14 (-0.21), DVA: 77.63 (+0.70), GILD: 101.81 (-1.61), SGEN: 35.32 (-0.28), ACHN: 11.39 (+0.40), MRK: 56.84 (-1.14), TEVA: 56.40 (-0.11), BIL: 45.72 (-0.01), ARIA: 8.08 (-0.17), NVS: 97.46 (-1.49)
Why Second Sight Medical Products Inc. Vaulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 27, 12:41PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Al Mann's vision-restoring...
EYES: 17.44 (+0.37), MNKD: 5.47 (-0.26)
